Separate and combined effects of the GABAA positive allosteric modulator diazepam and δ9-THC in humans discriminating δ9-THC

Drug and Alcohol Dependence

Volumn 143, Issue 1, 2014, Pages 141-148

  Lile, Joshua A ^a   Kelly, Thomas H ^a,b   Hays, Lon R ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cardiovascular; Digit symbol substitution task; Drug discrimination; Marijuana; Repeated acquisition task; Subjective effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CANNABIS; DIAZEPAM; DRONABINOL; PLACEBO; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST;

ADULT; ALLOSTERISM; ARTICLE; BLURRED VISION; BODY TEMPERATURE; CANNABIS ADDICTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG DOSE COMPARISON; FEMALE; HEART RATE; HUMAN; INTEROCEPTION; MALE; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; SEDATION; SELF REPORT; SIDE EFFECT; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TASK PERFORMANCE; ADOLESCENT; BLOOD PRESSURE; CANNABIS SMOKING; CONTROLLED CLINICAL TRIAL; DISCRIMINATION LEARNING; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; PSYCHOLOGY; YOUNG ADULT;

CANNABIS; CANNABIS SATIVA;

ADOLESCENT; ADULT; ALLOSTERIC REGULATION; BLOOD PRESSURE; BODY TEMPERATURE; CANNABINOID RECEPTOR AGONISTS; DIAZEPAM; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GABA MODULATORS; GABA-A RECEPTOR AGONISTS; HEART RATE; HUMANS; MALE; MARIJUANA SMOKING; PSYCHOMOTOR PERFORMANCE; RECEPTORS, GABA-A; YOUNG ADULT;

EID: 84922409014     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.07.016     Document Type: Article

References (38)

1. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC, (Text revision). 4th ed.
2. Barrett R.L., Wiley J.L., Balster R.L., Martin B.R. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 1995, 118:419-424.
3. Browne R.G., Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J. Clin. Pharmacol. 1981, 21:S227-S234.
4. Chutuape M.A., de Wit H. Relationship between subjective effects and drug preferences: ethanol and diazepam. Drug Alcohol Depend. 1994, 34:243-251.
5. de Wit H., Uhlenhuth E.H., Johanson C.E. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 1986, 16:341-360.
6. Evans S.M., Griffiths R.R., de Wit H. Preference for diazepam but not buspirone, in moderate drinkers. Psychopharmacology (Berl.) 1996, 123:154-163.
7. Glass R.M., Uhlenhuth E.H., Hartel F.W., Schuster C.R., Fischman M.W. Single-dose study of nabilone in anxious volunteers. J. Clin. Pharmacol. 1981, 21:S383-S396.
8. Greenblatt D.J. Pharmacology of benzodiazepine hypnotics. J. Clin. Psychiatry 1992, 53:7-13.
9. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry 2005, 66:31-41.
10. Griffiths R.R., Troisi J.R.I.I., Silverman K., Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 1993, 4:3-13.
11. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Foltin R.W. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl.) 2005, 181:237-243.
12. Heishman S.J., Stitzer M.L., Yingling J.E. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports and performance. Pharmacol. Biochem. Behav. 1989, 34:173-179.
13. Hillestad L., Hansen T., Melsom H., Drivenes A. Diazepam metabolism in normal man. I. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration. Clin. Pharmacol. Ther. 1974, 16:479-484.
14. Hollister L.E., Gillespie H.K., Ohlsson A., Lindgren J.E., Wahlen A., Agurell S. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?. J. Clin. Pharmacol. 1981, 21:171S-177S.
15. Järbe T.U., Hiltunen A.J. Limited stimulus generalization between delta 9-THC and diazepam in pigeons and gerbils. Psychopharmacology 1988, 94:328-331.
16. Kamien J.B., Bickel W.K., Higgins S.T., Hughes J.R. The effects of delta 9-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behav. Pharmacol. 1994, 5:71-78.
17. Kelly T.H., Delzer T.A., Martin C.A., Harrington N.G., Hays L.R., Bardo M.T. Performance and subjective effects of diazepam and d-amphetamine in high and low sensation seekers. Behav. Pharmacol. 2009, 20:505-517.
18. Kelly T.H., Foltin R.W., Emurian C.S., Fischman M.W. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol and diazepam. J. Anal. Toxicol. 1993, 17:264-272.
19. Kelly T.H., Foltin R.W., Fischman M.W. Multidimensional behavioral effects of marijuana. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14:885-902.
20. Lile J.A., Kelly T.H., Charnigo R.J., Stinchcomb A.L., Hays L.R. Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of δ(9)-THC in cannabis users. J. Clin. Pharmacol. 2013, 53:680-690.
21. 9-THC in humans discriminating δ(9)-THC. Drug Alcohol Depend. 2011, 116:86-92.
22. 9-THC in humans discriminating δ(9)-THC. Drug Alcohol Depend. 2012, 122:61-69.
23. 9-THC in humans discriminating δ(9)-THC. Drug Alcohol Depend. 2012, 126:216-223.
24. 9-tetrahydrocannabinol. Psychopharmacology 2009, 203:241-250.
25. Marinol® Product Information, 2006. Solvay Pharmaceuticals Inc.
26. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J.E. An automated version of the Digit Symbol Substitution Test (DSST). Behav. Res. Methods Instrum. 1982, 14:463-466.
27. Mokler D.J., Nelson B.D., Harris L.S., Rosecrans J.A. The role of benzodiazepine receptors in the discriminative stimulus properties of delta 9-tetrahydrocannabinol. Life Sci. 1986, 38:1581-1589.
28. Owen R.T., Tyrer P. Benzodiazepine dependence. A review of the evidence. Drugs 1983, 25:385-398.
29. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl.) 2006, 188:425-444.
30. Rush C.R., Kollins S.H., Pazzaglia P.J. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine trained humans. Exp. Clin. Psychopharmacol. 1998, 6:32-44.
31. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 2001, 22:565-572.
32. Toland S.L., Green W. DRE field testing of drug impaired drivers. The Effects of Drugs on Human Performance and Behavior: Drugs and Driving/Drugs in the Workplace 1991, American Academy of Forensic Sciences. V. Watts (Ed.).
33. Valium® Product Information, 2013. Genentech, Inc.
34. Vandrey R., Smith M.T., McCann U.D., Budney A.J., Curran E.M. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011, 117:38-44.
35. Wiley J.L., Martin B.R. Effects of SR141716A on diazepam substitution for delta 9-tetrahydrocannabinol in rat drug discrimination. Pharmacol. Biochem. Behav. 1999, 64:519-522.
36. Wiley J.L., Martin B.R. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur. J. Pharmacol. 2003, 471:185-193.
37. Wilson W.H., Ellinwood E.H., Mathew R.J., Johnson K. Effects of marijuana on performance of a computerized cognitive-neuromotor test battery. Psychiatry Res. 1994, 51:115-125.
38. 1 receptors in mood and anxiety disorders. Behav. Pharmacol. 2005, 16:315-331.